Neurosense Therapeutics Ltd. received a Buy rating and a $9.00 price target from Noble Financial analyst Robert LeBoyer on October 14. The company’s shares closed yesterday at $1.24.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, LeBoyer is an analyst with an average return of -9.3% and a 28.71% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Cadrenal Therapeutics, Inc., Nutriband, and Oncology Institute.
Currently, the analyst consensus on Neurosense Therapeutics Ltd. is a Moderate Buy with an average price target of $9.00.
The company has a one-year high of $2.60 and a one-year low of $0.80. Currently, Neurosense Therapeutics Ltd. has an average volume of 647K.
Read More on NRSN:
Disclaimer & DisclosureReport an Issue
- NeuroSense initiated with an Outperform at Noble Capital
- NeuroSense Announces Promising Alzheimer’s Biomarker Reductions with PrimeC
- NeuroSense announces ‘positive’ results from Phase-2b PARADIGM study
- NeuroSense Therapeutics Approves Resolutions at Annual Meeting
- NeuroSense Reports Positive Initial Results for Alzheimer’s Drug Candidate
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/AI%20(artificial%20intelligence)/AI%20engineer%20working%20on%20laptop%20by%20ART%20STOCK%20CREATIVE%20via%20Shutterstock.jpg)
/Nike%2C%20Inc_%20swish%20by-%20Tartezy%20via%20Shutterstock.jpg)
